Москвичи пожаловались на зловонную квартиру-свалку с телами животных и тараканами18:04
Последние новости
。51吃瓜对此有专业解读
Current and former employees of Google and OpenAI are invited to sign.
随着减重药巨头诺和诺德重磅GLP-1类药物司美格鲁肽在中国的核心分子专利即将于3月到期，一大批中国本土的司美格鲁肽仿制药正在获批路上。据公开信息，目前国内市场上包括九源基因、丽珠集团、华东医药、齐鲁制药、正大天晴在内的十多家本土制药公司的司美格鲁肽仿制药有望在不久的将来上市，还有十余款处于三期临床，一场价格大战即将席卷。一位内分泌专家表示，随着更多仿制药的上市，减重药很快就会迎来“白菜价”时代。（第一财经）
"The policy environment has shifted toward prioritizing AI competitiveness and economic growth, while safety-oriented discussions have yet to gain meaningful traction at the federal level," the company wrote. "We remain convinced that effective government engagement on AI safety is both necessary and achievable, and we aim to continue advancing a conversation grounded in evidence, national security interests, economic competitiveness, and public trust. But this is proving to be a long-term project—not something that is happening organically as AI becomes more capable or crosses certain thresholds."